PKIS v2.0 A clinical tool for identifying important pharmacokinetic drug-drug interactions
| 1. Accepted major perpetrators | 2. Rejected perpetrators | 3. Unclassifiable | 4. Full table |

diethyldithiocarbamate

  • diethyldithiocarbamate is not available in Australia/New Zealand, despite evidence suggesting that it may perturb the activities of CYP3A.
  • CYP3A
    Not available in Australia or New Zealandarmodafinil
    chloramphenicol [a]
    clotrimazole [a]
    conivaptan
    diethyldithiocarbamate
    mibefradil
    miconazole [a]
    nefazodone
    nelfinavir
    quinidine
    stiripentol
    sulfadimidine
    sulfinpyrazone
    telithromycin
    tofisopam
    troglitazone
    troleandomycin

    Footnotes and References

    a.systemic preparations not available in Australia or New Zealand.
    Disclaimer
    WARNING: While all efforts were put in to maintain the accuracy and currency of the information, it is possible that the knowledge and electronic tools may contain errors and inadequacy. Both Flinder's University and University of New South Wales are not liable to any damages or losses resulted from such circumstances. Clinical discretions are strongly advised at all times.